Research progress of therapeutic vaccines for treating chronic hepatitis B

References

• Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993; 342:1340-4; PMID:7694023; http://dx.doi.org/10.1016/0140-6736(93)92250-W
   PubMed Web of Science ®Google Scholar
• Dembek C, Protzer U. Mouse models for therapeutic vaccination against hepatitis B virus. Med Microbiol Immunol 2015; 204:95-102; PMID:25523197; http://dx.doi.org/10.1007/s00430-014-0378-6
   PubMed Web of Science ®Google Scholar
• Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011; 54:1286-96; PMID:21238516; http://dx.doi.org/10.1016/j.jhep.2010.12.031
   PubMed Web of Science ®Google Scholar
• H. OW. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization, 2015. PMID:25701223
   PubMedGoogle Scholar
• Michel ML. Towards immunotherapy for chronic hepatitis B virus infections. Vaccine 2002; 20(Suppl 4):A83-8; PMID:12477434; http://dx.doi.org/10.1016/S0264-410X(02)00393-6
   PubMed Web of Science ®Google Scholar
• Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci 2005; 2:50-7; PMID:15968340; http://dx.doi.org/10.7150/ijms.2.50
   PubMedGoogle Scholar
• Fazle Akbar SM, Al-Mahtab M, Hiasa Y. Designing immune therapy for chronic hepatitis B. J Clin Exp Hepatol 2014; 4:241-6; PMID:25755566; http://dx.doi.org/10.1016/j.jceh.2014.06.008
   PubMedGoogle Scholar
• Asselah T, Ripault MP, Castelnau C, Giuily N, Boyer N, Marcellin P. The current status of antiviral therapy of chronic hepatitis B. J Clin Virol 2005; 34(Suppl 1):S115-24; PMID:16461210; http://dx.doi.org/10.1016/S1386-6532(05)80020-4
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N England J Med 1997; 336:347-56; PMID:9011789; http://dx.doi.org/10.1056/NEJM199701303360507
   PubMed Web of Science ®Google Scholar
• Minami M. Future therapy for hepatitis B virus infection. Clin J Gastroenterol 2015; 8:167-71; PMID:26265385; http://dx.doi.org/10.1007/s12328-015-0590-y
   PubMedGoogle Scholar
• Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119:172-80.
   Google Scholar
• Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-22; PMID:14724824; http://dx.doi.org/10.1053/j.gastro.2003.09.033
   PubMed Web of Science ®Google Scholar
• Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49:S185-95; PMID:19399802; http://dx.doi.org/10.1002/hep.22885
   PubMed Web of Science ®Google Scholar
• Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, Jo HY, Lee CH, Kim DS. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009; 49:2080-6; PMID:19333909; http://dx.doi.org/10.1002/hep.22959
   PubMed Web of Science ®Google Scholar
• Kutscher S, Bauer T, Dembek C, Sprinzl M, Protzer U. Design of therapeutic vaccines: hepatitis B as an example. Microb Biotechnol 2012; 5:270-82; PMID:21958338; http://dx.doi.org/10.1111/j.1751-7915.2011.00303.x
   PubMed Web of Science ®Google Scholar
• Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5:215-29; PMID:15738952; http://dx.doi.org/10.1038/nri1573
   PubMed Web of Science ®Google Scholar
• Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29(Suppl 1):100-7; PMID:19207972; http://dx.doi.org/10.1111/j.1478-3231.2008.01941.x
   PubMed Web of Science ®Google Scholar
• Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143:963-73 e9; PMID:22796241; http://dx.doi.org/10.1053/j.gastro.2012.07.014
   PubMed Web of Science ®Google Scholar
• Maini MK, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. Journal of hepatology 2010; 52:616-9; PMID:20185199; http://dx.doi.org/10.1016/j.jhep.2009.12.017
   PubMed Web of Science ®Google Scholar
• Jung MC, Spengler U, Schraut W, Hoffmann R, Zachoval R, Eisenburg J, Eichenlaub D, Riethmüller G, Paumgartner G, Ziegler-Heitbrock HW, et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. Journal of hepatology 1991; 13:310-7; PMID:1808224; http://dx.doi.org/10.1016/0168-8278(91)90074-L
   PubMed Web of Science ®Google Scholar
• Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M, Chisari FV. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A 2010; 107:798-802; PMID:20080755; http://dx.doi.org/10.1073/pnas.0913498107
   PubMed Web of Science ®Google Scholar
• Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, Williams R, Dusheiko G, Bertoletti A. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78:5707-19; PMID:15140968; http://dx.doi.org/10.1128/JVI.78.11.5707-5719.2004
   PubMed Web of Science ®Google Scholar
• Liu H, Xiong Y, Shi L. Study on cellular immune response to large-dose HBsAg vaccine in transgenic mice. Medical Journal of Chinese Peoples Liberation Army 2005.
   Google Scholar
• Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, Denis J, Brécho C, Multicenter study group. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. Journal of hepatology 2001; 34:917-21; PMID:11451177; http://dx.doi.org/10.1016/S0168-8278(01)00028-9
   PubMed Web of Science ®Google Scholar
• Wen YM, Wu XH, Hu DC, Zhang QP, Guo SQ. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 1995; 345:1575-6; PMID:7791465; http://dx.doi.org/10.1016/S0140-6736(95)91126-X
   PubMed Web of Science ®Google Scholar
• Xu DZ, Huang KL, Zhao K, Xu LF, Shi N, Yuan ZH, Wen YM. Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine 2005; 23:2658-64; PMID:15780449; http://dx.doi.org/10.1016/j.vaccine.2004.10.040
   PubMed Web of Science ®Google Scholar
• Yao X, Zheng B, Zhou J, Xu DZ, Zhao K, Sun SH, Yuan ZH, Wen YM. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 2007; 25:1771-9; PMID:17224217; http://dx.doi.org/10.1016/j.vaccine.2006.11.019
   PubMed Web of Science ®Google Scholar
• Wang XY, Zhang XX, Yao X, Jiang JH, Xie YH, Yuan ZH, Wen YM. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. Vaccine 2010; 28:8169-74; PMID:20937312; http://dx.doi.org/10.1016/j.vaccine.2010.09.093
   PubMed Web of Science ®Google Scholar
• Xu DZ, Zhao K, Guo LM, Li LJ, Xie Q, Ren H, Zhang JM, Xu M, Wang HF, Huang WX, et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One 2008; 3:e2565; PMID:18596958; http://dx.doi.org/10.1371/journal.pone.0002565
   PubMed Web of Science ®Google Scholar
• Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. Journal of hepatology 2013; 59:450-6; PMID:23669281; http://dx.doi.org/10.1016/j.jhep.2013.05.003
   PubMed Web of Science ®Google Scholar
• Hoa PT, Huy NT, Thu le T, Nga CN, Nakao K, Eguchi K, Chi NH, Hoang BH, Hirayama K. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother 2009; 53:5134-40; PMID:19770281; http://dx.doi.org/10.1128/AAC.00276-09
   PubMed Web of Science ®Google Scholar
• Vandepapeliere P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican MI, Win KM, Trepo C, Cooksley G, et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007; 25:8585-97; PMID:18031872; http://dx.doi.org/10.1016/j.vaccine.2007.09.072
   PubMed Web of Science ®Google Scholar
• Spellman M MJ. Treatment of chronic hepatitis b infection with DV-601, a therapeutic vaccine. J Hepatol 2011; 54:s302; ; http://dx.doi.org/10.1016/S0168-8278(11)60753-8
   Google Scholar
• Al-Mahtab M AF, Uddin H, Rahman S, Aguilar Rubido JC. A phase III clinical trial with a nasal vaccine containing both HBsAg and HBcAg in patients with chronic Hepatitis B. Journal of hepatology 2013; 58:S229-S40; http://dx.doi.org/10.1016/S0168-8278(13)60778-3
   Google Scholar
• Li J, Ge J, Ren S, Zhou T, Sun Y, Sun H, Gu Y, Huang H, Xu Z, Chen X, et al. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection. Vaccine 2015; 33:4247-54; PMID:25858855; http://dx.doi.org/10.1016/j.vaccine.2015.03.079
   PubMed Web of Science ®Google Scholar
• Lok AS, Pan CQ, Han SH, Trinh HN, Fessel WJ, Rodell T, Massetto B, Lin L, Gaggar A, Subramanian GM, et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. Journal of hepatology 2016; 65:509-16; PMID:27210427; http://dx.doi.org/10.1016/j.jhep.2016.05.016
   PubMed Web of Science ®Google Scholar
• Godon O, Fontaine H, Kahi S, Meritet J, Scott-Algara D, Pol S, Michel M, Bourgine M. Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol Ther 2014; 22:675-84; PMID:24394187; http://dx.doi.org/10.1038/mt.2013.274
   PubMed Web of Science ®Google Scholar
• Fontaine H, Kahi S, Chazallon C, Bourgine M, Varaut A, Buffet C, Godon O, Meritet JF, Saïdi Y, Michel ML, et al. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial–ANRS HB02 VAC-ADN. Gut 2015; 64:139-47; PMID:24555998; http://dx.doi.org/10.1136/gutjnl-2013-305707
   PubMed Web of Science ®Google Scholar
• Yang SH, Lee CG, Park SH, Im SJ, Kim YM, Son JM, Wang JS, Yoon SK, Song MK, Ambrozaitis A, et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 2006; 13:1110-7; PMID:16525482; http://dx.doi.org/10.1038/sj.gt.3302751
   PubMed Web of Science ®Google Scholar
• Kim CY, Kang ES, Kim SB, Kim HE, Choi JH, Lee DS, Im SJ, Yang SH, Sung YC, Kim BM, et al. Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation. Exp Mol Med 2008; 40:669-76; PMID:19116452; http://dx.doi.org/10.3858/emm.2008.40.6.669
   PubMed Web of Science ®Google Scholar
• Paulsen D, Weber O, Ruebsamen-Schaeff H, Tennant BC, Menne S. AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B. PLoS One 2015; 10:e0144383; PMID:26656974; http://dx.doi.org/10.1371/journal.pone.0144383
   PubMed Web of Science ®Google Scholar
• Heathcote J, McHutchison J, Lee S, Tong M, Benner K, Minuk G, Wright T, Fikes J, Livingston B, Sette A, et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999; 30:531-6; PMID:10421664; http://dx.doi.org/10.1002/hep.510300208
   PubMed Web of Science ®Google Scholar
• Yang FQ, Rao GR. Research progress of therapeutic vaccines against hepatitis B. Infect Dis Info 2015; 28:65-9.
   Google Scholar
• Chen M, Li YG, Zhang DZ, Wang ZY, Zeng WQ, Shi XF, Guo Y, Guo SH, Ren H. Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study. World J Gastroenterol 2005; 11:1806-8; PMID:15793869; http://dx.doi.org/10.3748/wjg.v11.i12.1806
   PubMed Web of Science ®Google Scholar
• Protzer U, Abken H. Can engineered “designer” T cells outsmart chronic hepatitis B? Hepat Res Treat 2010; 2010:901216. PMID:21188203
   PubMedGoogle Scholar
• Sjogren MH. Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. American Journal of Medicine 2005; 118(Suppl 10A):34S-9S; PMID:16271539; http://dx.doi.org/10.1016/j.amjmed.2005.07.012
   PubMed Web of Science ®Google Scholar
• Dikici B, Bosnak M, Ucmak H, Dagli A, Ece A, Haspolat K. Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection. J Gastroenterol Hepatol 2003; 18:218-22; PMID:12542609; http://dx.doi.org/10.1046/j.1440-1746.2003.02950.x
   PubMed Web of Science ®Google Scholar
• Couillin I, Pol S, Mancini M, Driss F, Brechot C, Tiollais P, Michel ML. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999; 180:15-26; PMID:10353856; http://dx.doi.org/10.1086/314828
   PubMed Web of Science ®Google Scholar
• Mueller SN, Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2009; 106:8623-8; PMID:19433785; http://dx.doi.org/10.1073/pnas.0809818106
   PubMed Web of Science ®Google Scholar
• Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, Pilli M, Urbani S, Cavalli A, Cerioni S, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. Journal of hepatology 2003; 39:595-605; PMID:12971971; http://dx.doi.org/10.1016/S0168-8278(03)00292-7
   PubMed Web of Science ®Google Scholar
• Le Guerhier F, Thermet A, Guerret S, Chevallier M, Jamard C, Gibbs CS, Trépo C, Cova L, Zoulim F. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. Journal of hepatology 2003; 38:328-34; PMID:12586299; http://dx.doi.org/10.1016/S0168-8278(02)00425-7
   PubMed Web of Science ®Google Scholar
• Menne S, Roneker CA, Korba BE, Gerin JL, Tennant BC, Cote PJ. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol 2002; 76:5305-14; PMID:11991959; http://dx.doi.org/10.1128/JVI.76.11.5305-5314.2002
   PubMed Web of Science ®Google Scholar
• Akbar SM, Chen S, Al-Mahtab M, Abe M, Hiasa Y, Onji M. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. Antiviral Res 2012; 96:59-64; PMID:22884884; http://dx.doi.org/10.1016/j.antiviral.2012.07.011
   PubMed Web of Science ®Google Scholar
• Milich DR, Chen M, Schodel F, Peterson DL, Jones JE, Hughes JL. Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci U S A 1997; 94:14648-53; PMID:9405667; http://dx.doi.org/10.1073/pnas.94.26.14648
   PubMed Web of Science ®Google Scholar
• Aguilar JC, Lobaina Y, Muzio V, Garcia D, Penton E, Iglesias E, Pichardo D, Urquiza D, Rodríguez D, Silva D, et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 2004; 82:539-46; PMID:15479440; http://dx.doi.org/10.1111/j.0818-9641.2004.01278.x
   PubMed Web of Science ®Google Scholar
• Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillen G, Aguilar JC. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol 2005; 42:289-94; PMID:15589316; http://dx.doi.org/10.1016/j.molimm.2004.09.005
   PubMed Web of Science ®Google Scholar
• Buchmann P, Dembek C, Kuklick L, Jager C, Tedjokusumo R, von Freyend MJ, Drebber U, Janowicz Z, Melber K, Protzer U. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013; 31:1197-203; PMID:23306359; http://dx.doi.org/10.1016/j.vaccine.2012.12.074
   PubMed Web of Science ®Google Scholar
• Roth Y, Chapnik JS, Cole P. Feasibility of aerosol vaccination in humans. Ann Otol Rhinol Laryngol 2003; 112:264-70; PMID:12656420; http://dx.doi.org/10.1177/000348940311200313
   PubMed Web of Science ®Google Scholar
• Neutra MR, Pringault E, Kraehenbuhl JP. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu Rev Immunol 1996; 14:275-300; PMID:8717516; http://dx.doi.org/10.1146/annurev.immunol.14.1.275
   PubMed Web of Science ®Google Scholar
• Betancourt AA, Delgado CA, Estevez ZC, Martinez JC, Rios GV, Aureoles-Rosello SR, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 2007; 11:394-401; PMID:17257877; http://dx.doi.org/10.1016/j.ijid.2006.09.010
   PubMed Web of Science ®Google Scholar
• Al-Mahtab M, Akbar SM, Aguilar JC, Uddin MH, Khan MS, Rahman S. Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B. Hepatol Int 2013; 7:981-9; PMID:26202028; http://dx.doi.org/10.1007/s12072-013-9486-4
   PubMed Web of Science ®Google Scholar
• Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011; 10:499-511; PMID:21506647; http://dx.doi.org/10.1586/erv.10.174
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004; 24:693-701; PMID:15622454; http://dx.doi.org/10.1007/s10875-004-6244-3
   PubMed Web of Science ®Google Scholar
• Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003; 21:2461-7; PMID:12744879; http://dx.doi.org/10.1016/S0264-410X(03)00045-8
   PubMed Web of Science ®Google Scholar
• Gaggar A, Coeshott C, Apelian D, Rodell T, Armstrong BR, Shen G, Subramanian GM, McHutchison JG. Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. Vaccine 2014; 32:4925-31; PMID:25045824; http://dx.doi.org/10.1016/j.vaccine.2014.07.027
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol 2005; 175:633-9; PMID:16002657; http://dx.doi.org/10.4049/jimmunol.175.2.633
   PubMed Web of Science ®Google Scholar
• Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel ML. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 2006; 24:4482-9; PMID:16310901; http://dx.doi.org/10.1016/j.vaccine.2005.08.013
   PubMed Web of Science ®Google Scholar
• Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004; 40:874-82; PMID:15382173; http://dx.doi.org/10.1002/hep.20408
   PubMed Web of Science ®Google Scholar
• Yang FQ, Yu YY, Wang GQ, Chen J, Li JH, Li YQ, Rao GR, Mo GY, Luo XR, Chen GM. A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat 2012; 19:581-93; PMID:22762143; http://dx.doi.org/10.1111/j.1365-2893.2012.01589.x
   PubMed Web of Science ®Google Scholar
• Yoon SK, Seo YB, Im SJ, Bae SH, Song MJ, You CR, Jang JW, Yang SH, Suh YS, Song JS, et al. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int 2015; 35:805-15; PMID:24620920; http://dx.doi.org/10.1111/liv.12530
   PubMed Web of Science ®Google Scholar
• Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A 1996; 93:11349-53.
   PubMed Web of Science ®Google Scholar
• Tatsis N, Ertl HCJ. Adenoviruses as Vaccine Vectors. Mol Ther J Am Soc Gene Ther 2004; 10:616-29; PMID:15451446; http://dx.doi.org/10.1016/j.ymthe.2004.07.013
   PubMed Web of Science ®Google Scholar
• Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, Kratzer R, Lelu-Santolaria K, Evlachev A, Meritet JF, et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut 2015; 64:1961-71; PMID:25429051; http://dx.doi.org/10.1136/gutjnl-2014-308041
   PubMed Web of Science ®Google Scholar
• Shi TD, Wu YZ, Jia ZC, Zou LY, Zhou W. Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs. World J Gastroenterol 2004; 10:1902-6; PMID:15222033; http://dx.doi.org/10.3748/wjg.v10.i13.1902
   PubMed Web of Science ®Google Scholar
• Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, Oh S, Fay J, Pascual V, Banchereau J, et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010; 234:199-212; PMID:20193020; http://dx.doi.org/10.1111/j.0105-2896.2009.00884.x
   PubMed Web of Science ®Google Scholar
• Fazle Akbar SM, Furukawa S, Onji M, Murata Y, Niya T, Kanno S, Murakami H, Horiike N, et al. Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. Hepatol Res 2004; 29:136-41; PMID:15203076; http://dx.doi.org/10.1016/j.hepres.2004.03.003
   PubMed Web of Science ®Google Scholar
• June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007; 117:1204-12; PMID:17476350; http://dx.doi.org/10.1172/JCI31446
   PubMed Web of Science ®Google Scholar
• Hawkins RE, Gilham DE, Debets R, Eshhar Z, Taylor N, Abken H, Schumacher TN, ATTACK Consortium. Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther 2010; 21:665-72; PMID:20408760; http://dx.doi.org/10.1089/hum.2010.086
   PubMed Web of Science ®Google Scholar
• Hui CK, Lie A, Au WY, Leung YH, Ma SY, Cheung WW, Zhang HY, Chim CS, Kwong YL, Liang R, et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 2005; 106:464-9; PMID:15797991; http://dx.doi.org/10.1182/blood-2005-02-0698
   PubMed Web of Science ®Google Scholar
• Bohne F, Chmielewski M, Ebert G, Wiegmann K, Kurschner T, Schulze A, Urban S, Krönke M, Abken H, Protzer U. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 2008; 134:239-47; PMID:18166356; http://dx.doi.org/10.1053/j.gastro.2007.11.002
   PubMed Web of Science ®Google Scholar
• Zhang TY, Yuan Q, Zhao JH, Zhang YL, Yuan LZ, Lan Y, Lo YC, Sun CP, Wu CR, Zhang JF, et al. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut 2016; 65:658-71; PMID:26423112; http://dx.doi.org/10.1136/gutjnl-2014-308964
   PubMed Web of Science ®Google Scholar
• Tsuge M, Hiraga N, Uchida T, Kan H, Miyaki E, Masaki K, Ono A, Nakahara T, Abe-Chayama H, Zhang Y, et al. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection. J Gastroenterol 2016; 51:1073-80; PMID:26943168; http://dx.doi.org/10.1007/s00535-016-1189-x
   PubMed Web of Science ®Google Scholar
• Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1:e00049; PMID:23150796; http://dx.doi.org/10.7554/eLife.00049
   PubMed Web of Science ®Google Scholar